Lineage Cell Therapeutics(US:LCTX)2021-10-01 18:30Corporate Overview - Lineage Cell Therapeutics aims to pioneer a new branch of medicine based on transplanting specific cell types into the body[4] - The company possesses a unique advantage in manufacturing an unlimited supply of specialized cell types from established pluripotent cell lines[5,7] - As of June 30, 2021, Lineage Cell Therapeutics had approximately $687 million in cash and marketable securities, with a market capitalization of around $434 million as of August 12, 2021[5] OpRegen Program (Dry AMD) - Dry Age-Related Macular Degeneration (AMD) affects approximately 11 million people in the United States, with 85-90% of cases being dry AMD, a market with no approved therapies yet[13,14] - The market for Wet AMD has annual sales of over $10 billion[13,14] - OpRegen, an RPE cell transplant, has shown retinal tissue restoration in three clinical cases[5,20] - In Cohort 4, 67% of OpRegen-treated eyes were at or above baseline visual acuity, while visual acuity declined in 75% of untreated eyes[20] - Current production scale for OpRegen is 5 billion cells per 3-liter bioreactor, equal to 2,500 clinical doses per batch[17] OPC1 Program (Spinal Cord Injury) - Lifetime care for a Spinal Cord Injury (SCI) patient can cost nearly $5 million[44,45] - OPC1 has received over $14 million in support from the California Institute for Regenerative Medicine (CIRM)[10,53] - In the SCiStar clinical trial, 96% of OPC1 patients had serial MRI scans indicating no sign of a lesion cavity at 12 months[58] - 32% of patients in the SCiStar clinical trial gained two or more motor levels of improvement[5,59] VAC Program (Cancer) - The VAC platform leverages large-scale production of dendritic cells (DCs) loaded with tumor or viral antigens to create targeted immune responses[74,75]